WO2009057784A1 - 複素環化合物 - Google Patents

複素環化合物 Download PDF

Info

Publication number
WO2009057784A1
WO2009057784A1 PCT/JP2008/069967 JP2008069967W WO2009057784A1 WO 2009057784 A1 WO2009057784 A1 WO 2009057784A1 JP 2008069967 W JP2008069967 W JP 2008069967W WO 2009057784 A1 WO2009057784 A1 WO 2009057784A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
hydrogen atom
heterocyclic compound
optionally substituted
compound represented
Prior art date
Application number
PCT/JP2008/069967
Other languages
English (en)
French (fr)
Inventor
Yoshihiro Banno
Ryoma Hara
Ryosuke Tokunoh
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Priority to US12/734,427 priority Critical patent/US8309580B2/en
Priority to JP2009539145A priority patent/JP5450083B2/ja
Priority to EP20080844600 priority patent/EP2210876B1/en
Publication of WO2009057784A1 publication Critical patent/WO2009057784A1/ja

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40Radicals substituted by oxygen atoms
    • C07D307/42Singly bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

 本発明は、糖尿病等の予防・治療に有用な、グルカゴン拮抗作用を有する、下式(I)で表される複素環化合物を提供する: [式中、環Aは、置換されていてもよいベンゼン環など;Yは、窒素原子など;Xは、-O-など;R4は、水素原子など;R5およびR6は、独立して、水素原子など;R1は、置換されていてもよい炭化水素基など;R2は、水素原子など;R3は、-(CH2)3-COOHなどを示す。]で表される化合物またはその塩。
PCT/JP2008/069967 2007-11-01 2008-10-31 複素環化合物 WO2009057784A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/734,427 US8309580B2 (en) 2007-11-01 2008-10-31 Heterocyclic compound
JP2009539145A JP5450083B2 (ja) 2007-11-01 2008-10-31 複素環化合物
EP20080844600 EP2210876B1 (en) 2007-11-01 2008-10-31 Heterocyclic compound as glucagon antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-285526 2007-11-01
JP2007285526 2007-11-01

Publications (1)

Publication Number Publication Date
WO2009057784A1 true WO2009057784A1 (ja) 2009-05-07

Family

ID=40591164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069967 WO2009057784A1 (ja) 2007-11-01 2008-10-31 複素環化合物

Country Status (4)

Country Link
US (1) US8309580B2 (ja)
EP (1) EP2210876B1 (ja)
JP (1) JP5450083B2 (ja)
WO (1) WO2009057784A1 (ja)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027849A1 (ja) * 2009-09-04 2011-03-10 武田薬品工業株式会社 複素環化合物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8507533B2 (en) 2011-02-08 2013-08-13 Pfizer Inc. Glucagon receptor modulators
WO2013147026A1 (ja) 2012-03-29 2013-10-03 武田薬品工業株式会社 芳香環化合物
JP2014500306A (ja) * 2010-12-23 2014-01-09 ファイザー・インク グルカゴン受容体モジュレーター
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054984A1 (en) * 2007-10-24 2009-04-30 Merck & Co., Inc. Heterocycle phenyl amide t-type calcium channel antagonists
GEP20135844B (en) 2008-03-05 2013-06-10 Takeda Pharmaceutical Heterocyclic compound
US8722731B2 (en) 2010-06-07 2014-05-13 Novomedix, Llc Furanyl compounds and the use thereof
US10882837B2 (en) * 2017-01-24 2021-01-05 Alphala Co., Ltd. Amide compounds and use thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
WO2001014372A2 (en) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2001082925A1 (fr) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone concentrant la melanine
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
JP2002544254A (ja) * 1999-05-17 2002-12-24 ノボ ノルディスク アクティーゼルスカブ グルカゴンアンタゴニスト/逆アゴニスト
GB2387172A (en) * 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
WO2004002480A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
WO2004069158A2 (en) 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
WO2004098528A2 (en) 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
JP2005511683A (ja) * 2001-12-03 2005-04-28 ノボ ノルディスク アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
WO2006102067A1 (en) 2005-03-21 2006-09-28 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives
US20070060623A1 (en) 2005-08-20 2007-03-15 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
EP1803709A1 (en) 2004-09-30 2007-07-04 Takeda Pharmaceutical Company Limited Proton pump inhibitors
WO2007091396A1 (ja) * 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 新規アミドプロピオン酸誘導体およびこれを含有する医薬

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
GEP20135844B (en) 2008-03-05 2013-06-10 Takeda Pharmaceutical Heterocyclic compound

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JP2002544254A (ja) * 1999-05-17 2002-12-24 ノボ ノルディスク アクティーゼルスカブ グルカゴンアンタゴニスト/逆アゴニスト
WO2001014372A2 (en) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2001082925A1 (fr) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone concentrant la melanine
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
JP2005511683A (ja) * 2001-12-03 2005-04-28 ノボ ノルディスク アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
GB2387172A (en) * 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
WO2004002480A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
JP2006500325A (ja) * 2002-06-27 2006-01-05 ノボ ノルディスク アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
JP2006516622A (ja) * 2003-01-27 2006-07-06 メルク エンド カムパニー インコーポレーテッド 置換ピラゾール、このような化合物を含有する組成物及び使用方法
WO2004069158A2 (en) 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
WO2004098528A2 (en) 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
EP1803709A1 (en) 2004-09-30 2007-07-04 Takeda Pharmaceutical Company Limited Proton pump inhibitors
WO2006102067A1 (en) 2005-03-21 2006-09-28 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives
US20070060623A1 (en) 2005-08-20 2007-03-15 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
WO2007091396A1 (ja) * 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 新規アミドプロピオン酸誘導体およびこれを含有する医薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IYAKUHIN NO KAIHATSU: "(Development of Pharmaceuticals),", vol. 7, 1990, PUBLISHED BY HIROKAWA SHOTEN, DESIGN OF MOLECULES, pages: 163 - 198
See also references of EP2210876A4 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027849A1 (ja) * 2009-09-04 2011-03-10 武田薬品工業株式会社 複素環化合物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2014500306A (ja) * 2010-12-23 2014-01-09 ファイザー・インク グルカゴン受容体モジュレーター
US8933104B2 (en) 2010-12-23 2015-01-13 Pfizer Inc. Glucagon receptor modulators
US8809342B2 (en) 2010-12-23 2014-08-19 Pfizer Inc. Glucagon receptor modulators
US9056834B2 (en) 2010-12-23 2015-06-16 Pfizer Inc. Glucagon receptor modulators
US8507533B2 (en) 2011-02-08 2013-08-13 Pfizer Inc. Glucagon receptor modulators
US9452999B2 (en) 2011-02-08 2016-09-27 Pfizer Inc. Glucagon receptor modulators
US9073871B2 (en) 2011-02-08 2015-07-07 Pfizer Inc. Glucagon receptor modulators
US8859591B2 (en) 2011-02-08 2014-10-14 Pfizer Inc. Glucagon receptor modulators
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
US9139538B2 (en) 2011-07-22 2015-09-22 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9073864B2 (en) 2012-03-29 2015-07-07 Takeda Pharmaceutical Company Limted Aromatic ring compound
WO2013147026A1 (ja) 2012-03-29 2013-10-03 武田薬品工業株式会社 芳香環化合物

Also Published As

Publication number Publication date
JPWO2009057784A1 (ja) 2011-03-10
US8309580B2 (en) 2012-11-13
JP5450083B2 (ja) 2014-03-26
EP2210876B1 (en) 2015-05-20
EP2210876A1 (en) 2010-07-28
US20100256156A1 (en) 2010-10-07
EP2210876A4 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
WO2009057784A1 (ja) 複素環化合物
WO2005097129A3 (en) 6-azaindole compound
JO2791B1 (en) Acid secretion inhibitor
WO2009028543A1 (ja) 置換ピラゾール誘導体
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
WO2008108380A3 (en) Pyrrole compounds
JO3259B1 (ar) مشتق دائري مغاير ملتحم واستخدامه
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
EP1968131A4 (en) ORGANIC ELECTROLUMINESCENT DEVICE AND MATERIAL THEREFOR
WO2009016462A3 (en) Substituted bicyclolactam compounds
WO2009016841A1 (ja) オキソピラジン誘導体及び除草剤
WO2008057855A9 (en) Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity
WO2009038064A1 (ja) I型11βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
MY152972A (en) Azabicyclo compound and salt thereof
UA95972C2 (ru) Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
MX2010008039A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos.
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
WO2006135828A3 (en) Trisubstituted amines as phosphodiesterase 4 inhibitors
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
TW200609218A (en) Bicyclic compounds
EP1790636A4 (en) PIPERIDINE DERIVATIVES AND THEIR USE
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
MX2010001566A (es) Derivado de aminopirazolamida.
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators
WO2008114812A1 (ja) Jak阻害剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08844600

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009539145

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008844600

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12734427

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE